Ascendis Pharma A/S (ASND) Earnings Date, Estimates & Call Transcripts → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free asnd Stock Alerts $136.93 -6.25 (-4.37%) (As of 04/25/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryLatest Earnings DateFeb. 7EstimatedActual EPS (Feb. 7) -$1.66 Beat By $0.49 Consensus EPS (Feb. 7) -$2.15 Get Ascendis Pharma A/S Earnings AlertsEnter your email address below to receive the latest news and earnings results for ASND and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueASND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ASND Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. Ascendis Pharma A/S Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($2.16)($2.16)($2.16)Q2 20242($1.76)($1.07)($1.42)Q3 20242($1.40)($0.50)($0.95)Q4 20242($0.95)($0.17)($0.56)FY 20247($6.27)($3.90)($5.09)ASND Earnings Date and InformationAscendis Pharma A/S last posted its quarterly earnings results on February 7th, 2024. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S has generated ($9.25) earnings per share over the last year (($9.25) diluted earnings per share). Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.15) to ($0.36) per share. Read More Ascendis Pharma A/S Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript2/7/2024Q4 2023($2.15)($1.66)+$0.49($1.66)$97.02 million$148.62 million11/7/2023Q3 2023($2.63)($3.12)($0.49)($3.12)$52.54 million$52.02 million9/5/2023Q2 2023($2.68)($2.35)+$0.33($2.35)$41.73 million$51.59 million4/27/2023Q1 2023($2.84)($2.12)+$0.72($2.12)$24.53 million$36.04 million2/16/2023Q4 2022($2.50)($3.78)($1.28)($3.78)$20.31 million$23.38 million11/2/2022Q3 2022($2.52)($3.05)($0.53)($3.05)$10.67 million$15.41 million Get the Latest News and Ratings for ASND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. 8/10/2022Q2 2022($2.11)($1.54)+$0.57($1.54)$7.07 million$6.51 million5/11/2022Q1 2022($2.25)($2.48)($0.23)($2.48)$5.89 million$7.66 million 3/2/2022Q4 2021($2.57)($2.14)+$0.43($2.14)$2.78 million$5.60 million 11/9/2021Q3 2021($2.60)($1.47)+$1.13($1.73)$1.60 million$1.31 million 8/24/2021Q2 2021($2.75)($2.50)+$0.25($3.01)$1.46 million$1.23 million 5/26/2021Q1 2021($2.06)($1.17)+$0.89($1.41)$1.94 million$0.90 million Ascendis Pharma A/S Earnings - Frequently Asked Questions When did Ascendis Pharma A/S announce their last quarterly earnings? Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earning data on Wednesday, February 7, 2024. Learn more on ASND's earnings history. Did Ascendis Pharma A/S beat their earnings estimates last quarter? In the previous quarter, Ascendis Pharma A/S (NASDAQ:ASND) reported ($1.66) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.15) by $0.49. Learn more on analysts' earnings estimate vs. ASND's actual earnings. How much revenue does Ascendis Pharma A/S generate each year? Ascendis Pharma A/S (NASDAQ:ASND) has a recorded annual revenue of $288.08 million. How much profit does Ascendis Pharma A/S generate each year? Ascendis Pharma A/S (NASDAQ:ASND) has a recorded net income of -$521.07 million. ASND has generated -$9.25 earnings per share over the last four quarters. What is Ascendis Pharma A/S's EPS forecast for next year? Ascendis Pharma A/S's earnings are expected to grow from ($4.15) per share to ($0.36) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ITCI Earnings Date CERE Earnings Date VKTX Earnings Date LEGN Earnings Date CYTK Earnings Date JAZZ Earnings Date ELAN Earnings Date CTLT Earnings Date APLS Earnings Date IONS Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:ASND) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.